{Reference Type}: Practice Guideline
{Title}: ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements.
{Author}: Crespo MM;Claridge T;Domsic RT;Hartwig M;Kukreja J;Stratton K;Chan KM;Molina M;Ging P;Cochrane A;Hoetzenecker K;Ahmad U;Kapnadak S;Timofte I;Verleden G;Lyu D;Quddus S;Davis N;Porteous M;Mallea J;Perch M;Distler O;Highland K;Magnusson J;Vos R;Glanville AR;
{Journal}: J Heart Lung Transplant
{Volume}: 40
{Issue}: 11
{Year}: 11 2021
{Factor}: 13.569
{DOI}: 10.1016/j.healun.2021.07.013
{Abstract}: Patients with connective tissues disease (CTD) are often on immunomodulatory agents before lung transplantation (LTx). Till now, there's no consensus on the safety of using these agents perioperative and post-transplant. The International Society for Heart and Lung Transplantation-supported consensus document on LTx in patients with CTD addresses the risk and contraindications of perioperative and post-transplant management of the biologic disease-modifying antirheumatic drugs (bDMARD), kinase inhibitor DMARD, and biologic agents used for LTx candidates with underlying CTD, and the recommendations and management of non-gastrointestinal extrapulmonary manifestations, and esophageal disorders by medical and surgical approaches for CTD transplant recipients.